title: Trends in antiparkinsonian medication use in new zealand: 1995-2011.
abstract: Prescribing trends for medications are influenced by development of new drugs, changes in knowledge about efficacy and side effects, and priorities set by funding agencies. Changes in the utilization of antiparkinsonian agents in the outpatient community in New Zealand were investigated by using the national prescription database for the period 1995-2011. The dispensed volumes of antiparkinsonian agents were converted into number of defined daily doses per 1000 inhabitants per day for analysis. Increases in the dispensed volumes of levodopa (77%), amantadine (350%), and catechol-o-methyl transferase inhibitors (326%) occurred during the study period. Conversely, decreases in the dispensed volumes of anticholinergics (48%), selegiline (82%), and dopamine agonists (6.2%) were observed. New Zealand has seen a substantial increase of the amount of levodopa dispensed in the past 17 years. This increase appears to be related to an increase in the number of people taking the medication. We are unable to extrapolate this change to an increase in the prevalence of PD, given levodopa is used in the treatment of a number of medical conditions. The changes in other antiparkinsonian medications largely reflect changes in availability (increases in entacapone and ropinirole) and best practice treatment (declines in anticholinergics, selegiline, and tolcapone).
authors.affiliation: Department of Medicine, University of Otago, Christchurch, P.O. Box 4345, Christchurch 8140, New Zealand ; New Zealand Brain Research Institute, 66 Stewart Street, Christchurch 8011, New Zealand.
authors.forename: T L
authors.initials: TL
authors.lastname: Pitcher
authors.affiliation: Department of Medicine, University of Otago, Christchurch, P.O. Box 4345, Christchurch 8140, New Zealand ; New Zealand Brain Research Institute, 66 Stewart Street, Christchurch 8011, New Zealand.
authors.forename: M R
authors.initials: MR
authors.lastname: Macaskill
authors.affiliation: Department of Medicine, University of Otago, Christchurch, P.O. Box 4345, Christchurch 8140, New Zealand ; New Zealand Brain Research Institute, 66 Stewart Street, Christchurch 8011, New Zealand ; Department of Neurology, Canterbury District Health Board, Private Bag 4710, Christchurch 8140, New Zealand.
authors.forename: T J
authors.initials: TJ
authors.lastname: Anderson
references.citation: Drugs. 2000 Jun;59(6):1233-50
references.pmid: 10882160
references.citation: Acta Neurol Scand. 1992 Jul;86(1):40-4
references.pmid: 1519473
references.citation: Brain. 1966 Sep;89(3):429-48
references.pmid: 5921126
references.citation: Cochrane Database Syst Rev. 2003;(2):CD003467
references.pmid: 12804468
references.citation: Arch Neurol. 2000 Feb;57(2):263-7
references.pmid: 10681087
references.citation: JAMA. 1969 May 19;208(7):1168-70
references.pmid: 5818715
references.citation: Mov Disord. 2009 Jan 15;24(1):129-33
references.pmid: 19170199
references.citation: Lancet. 2012 Dec 15;380(9859):2071-94
references.pmid: 23245603
references.citation: Cochrane Database Syst Rev. 2003;(2):CD003735
references.pmid: 12804486
references.citation: Mov Disord. 2010 Jun 15;25(8):1053-60
references.pmid: 20222132
references.citation: Annu Rev Med. 2013;64:393-406
references.pmid: 23020880
references.citation: Parkinsonism Relat Disord. 2007 Dec;13(8):500-4
references.pmid: 17532251
references.citation: Acta Neurol Scand. 1995 Feb;91(2):89-97
references.pmid: 7785430
references.citation: Mov Disord. 2013 Mar;28(3):311-8
references.pmid: 23436720
references.citation: J Neurol Neurosurg Psychiatry. 1999 Jan;66(1):79-81
references.pmid: 9886458
references.citation: BMJ. 1995 Dec 16;311(7020):1602-7
references.pmid: 8555803
references.citation: Acta Neurol Scand. 1995 Feb;91(2):79-88
references.pmid: 7785429
references.citation: BMJ. 1998 Apr 18;316(7139):1191-6
references.pmid: 9583926